MDxHealth SA (NASDAQ:MDXH) Receives Average Rating of “Hold” from Analysts

Shares of MDxHealth SA (NASDAQ:MDXH) have received an average rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $2.1667.

Several research firms have commented on MDXH. BTIG Research lowered their price objective on MDxHealth from $4.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, August 21st. Wall Street Zen upgraded shares of MDxHealth to a “sell” rating in a research note on Saturday, August 15th. William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. TD Cowen restated a “buy” rating and set a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. Finally, Lake Street Capital set a $3.00 price objective on shares of MDxHealth and gave the company a “buy” rating in a report on Friday, August 14th.

MDxHealth Stock Down 4.7%

Shares of MDXH opened at $0.71 on Wednesday. The company has a market capitalization of $35.32 million, a price-to-earnings ratio of -0.99 and a beta of 1.57. MDxHealth has a 52 week low of $0.40 and a 52 week high of $5.33. The stock’s 50-day moving average price is $0.55 and its 200-day moving average price is $1.43.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. The company had revenue of $27.21 million for the quarter, compared to analysts’ expectations of $26.14 million. As a group, equities analysts anticipate that MDxHealth will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

Large investors have recently bought and sold shares of the business. Intesa Sanpaolo Wealth Management purchased a new position in MDxHealth during the fourth quarter worth approximately $36,000. Lido Advisors LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth approximately $48,000. Squarepoint Ops LLC acquired a new position in shares of MDxHealth during the 4th quarter worth approximately $51,000. Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth during the 3rd quarter valued at approximately $53,000. Finally, Balyasny Asset Management L.P. acquired a new stake in MDxHealth in the 4th quarter valued at $68,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.